The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
β-Arrestin-mediated activation of MAPK by inverse agonists reveals distinct active conformations for G protein-coupled receptors
Open accessAbstract
It is becoming increasingly clear that signaling via G protein-coupled receptors is a diverse phenomenon involving receptor interaction with a variety of signaling partners. Despite this diversity, receptor ligands are commonly classified only according to their ability to modify G protein-dependent signaling. Here we show that β 2 AR ligands like ICI118551 and propranolol, which are inverse agonists for Gs-stimulated adenylyl cyclase, induce partial agonist responses for the mitogen-activated protein kinases extracellular signal-regulated kinase (ERK) 1/2 thus behaving as dual efficacy ligands. ERK1/2 activation by dual efficacy ligands was not affected by ADP-ribosylation of Gαi and could be observed in S49-cyc – cells lacking Gαs indicating that, unlike the conventional agonist isoproterenol, these drugs induce ERK1/2 activation in a Gs/i-independent manner. In contrast, this activation was inhibited by a dominant negative mutant of β-arrestin and was abolished in mouse embryonic fibroblasts lacking β-arrestin 1 and 2. The role of β-arrestin was further confirmed by showing that transfection of β-arrestin 2 in these knockout cells restored ICI118551 promoted ERK1/2 activation. ICI118551 and propranolol also promoted β-arrestin recruitment to the receptor. Taken together, these observations suggest that β-arrestin recruitment is not an exclusive property of agonists, and that ligands classically classified as inverse agonists rely exclusively on β-arrestin for their positive signaling activity. This phenomenon is not unique to β 2 -adrenergic ligands because SR121463B, an inverse agonist on the V2 vasopressin receptor-stimulated adenylyl cyclase, recruited β-arrestin and stimulated ERK1/2. These results point to a multistate model of receptor activation in which ligand-specific conformations are capable of differentially activating distinct signaling partners.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4
LAEMMLI, U. K. (1970) · Nature · doi:10.1038/227680a0 · Cited by 249,961
Raza, H., John, A., & Nemmar, A. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350087 · Cited by 47,221
β-Arrestin-Dependent Formation of β 2 Adrenergic Receptor-Src Protein Kinase Complexes
Luttrell, L. M., Ferguson, S. S. G., Daaka, Y., Miller, W. E., Maudsley, S., Della Rocca, G. J., Lin, F.-T., Kawakatsu, H., Owada, K., Luttrell, D. K., et al. (1999) · Science · doi:10.1126/science.283.5402.655 · Cited by 1,475
β-Arrestin acts as a clathrin adaptor in endocytosis of the β2-adrenergic receptor
Goodman, O. B., Krupnick, J. G., Santini, F., Gurevich, V. V., Penn, R. B., Gagnon, A. W., Keen, J. H., & Benovic, J. L. (1996) · Nature · doi:10.1038/383447a0 · Cited by 1,384
Switching of the coupling of the β2-adrenergic receptor to different G proteins by protein kinase A
Daaka, Y., Luttrell, L. M., & Lefkowitz, R. J. (1997) · Nature · doi:10.1038/36362 · Cited by 1,270
Activation and targeting of extracellular signal-regulated kinases by β-arrestin scaffolds
Luttrell, L. M., Roudabush, F. L., Choy, E. W., Miller, W. E., Field, M. E., Pierce, K. L., & Lefkowitz, R. J. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.041604898 · Cited by 831
DeFea, K. A., Zalevsky, J., Thoma, M. S., Déry, O., Mullins, R. D., & Bunnett, N. W. (2000) · The Journal of Cell Biology · doi:10.1083/jcb.148.6.1267 · Cited by 822
β-Arrestin 2: A Receptor-Regulated MAPK Scaffold for the Activation of JNK3
McDonald, P. H., Chow, C.-W., Miller, W. E., Laporte, S. A., Field, M. E., Lin, F.-T., Davis, R. J., & Lefkowitz, R. J. (2000) · Science · doi:10.1126/science.290.5496.1574 · Cited by 819
Angers, S., Salahpour, A., Joly, E., Hilairet, S., Chelsky, D., Dennis, M., & Bouvier, M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.7.3684 · Cited by 638
Self-citationOakley, R. H., Laporte, S. A., Holt, J. A., Barak, L. S., & Caron, M. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.45.32248 · Cited by 567
Cited by
Crystal structure of the β2 adrenergic receptor–Gs protein complex
Rasmussen, S. G. F., DeVree, B. T., Zou, Y., Kruse, A. C., Chung, K. Y., Kobilka, T. S., Thian, F. S., Chae, P. S., Pardon, E., Calinski, D., et al. (2011) · Nature · doi:10.1038/nature10361 · Cited by 3,009
The structure and function of G-protein-coupled receptors
Rosenbaum, D. M., Rasmussen, S. G. F., & Kobilka, B. K. (2009) · Nature · doi:10.1038/nature08144 · Cited by 2,534
Transduction of Receptor Signals by ß-Arrestins
Lefkowitz, R. J., & Shenoy, S. K. (2005) · Science · doi:10.1126/science.1109237 · Cited by 1,727
β-Arrestins and Cell Signaling
DeWire, S. M., Ahn, S., Lefkowitz, R. J., & Shenoy, S. K. (2007) · Annual Review of Physiology · doi:10.1146/annurev.physiol.69.022405.154749 · Cited by 1,397
Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance
Williams, J. T., Ingram, S. L., Henderson, G., Chavkin, C., von Zastrow, M., Schulz, S., Koch, T., Evans, C. J., & Christie, M. J. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005942 · Cited by 802
Temporally precise in vivo control of intracellular signalling
Airan, R. D., Thompson, K. R., Fenno, L. E., Bernstein, H., & Deisseroth, K. (2009) · Nature · doi:10.1038/nature07926 · Cited by 724
Conformational complexity of G-protein-coupled receptors
Kobilka, B. K., & Deupi, X. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.003 · Cited by 694
GRKs and β-arrestins: roles in receptor silencing, trafficking and signaling
Reiter, E., & Lefkowitz, R. J. (2006) · Trends in Endocrinology & Metabolism · doi:10.1016/j.tem.2006.03.008 · Cited by 666
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647
“…including coupling to different Ga subunits (Spengler et al., 1993; Eason et al., 1994), and between G protein coupling and b-arrestin recruitment (Azzi et al., 2003; Gesty-Palmer et al., 2006; DeWire et al., 2007; Violin and Lefkowitz, 2007; Kim et al., 2008; Ma et al., 2009; Gesty-Palmer and…”
BackgroundG protein coupled receptor structure and activation
Kobilka, B. K. (2007) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2006.10.021 · Cited by 623
A unique mechanism of β-blocker action: Carvedilol stimulates β-arrestin signaling
Wisler, J. W., DeWire, S. M., Whalen, E. J., Violin, J. D., Drake, M. T., Ahn, S., Shenoy, S. K., & Lefkowitz, R. J. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707936104 · Cited by 597
Molecular Mechanism of β-Arrestin-Biased Agonism at Seven-Transmembrane Receptors
Reiter, E., Ahn, S., Shukla, A. K., & Lefkowitz, R. J. (2012) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.010909.105800 · Cited by 583
Kenakin, T., & Miller, L. J. (2010) · Pharmacological Reviews · doi:10.1124/pr.108.000992 · Cited by 573
The selectivity of β‐adrenoceptor antagonists at the human β 1, β 2 and β 3 adrenoceptors
Baker, J. G. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706048 · Cited by 537
Therapeutic potential of β-arrestin- and G protein-biased agonists
Whalen, E. J., Rajagopal, S., & Lefkowitz, R. J. (2011) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.11.004 · Cited by 510
Functional Selectivity and Biased Receptor Signaling
Kenakin, T. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.173948 · Cited by 505
Gesty-Palmer, D., Chen, M., Reiter, E., Ahn, S., Nelson, C. D., Wang, S., Eckhardt, A. E., Cowan, C. L., Spurney, R. F., Luttrell, L. M., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513380200 · Cited by 476
Beyond Desensitization: Physiological Relevance of Arrestin-Dependent Signaling
Luttrell, L. M., Gesty-Palmer, D., & Sibley, D. R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002436 · Cited by 369
Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology
Leach, K., Sexton, P. M., & Christopoulos, A. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.004 · Cited by 363
The evasive nature of drug efficacy: implications for drug discovery
Galandrin, S., Oligny-Longpré, G., & Bouvier, M. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.06.005 · Cited by 363
Self-citationAllosteric Modulation as a Unifying Mechanism for Receptor Function and Regulation
Changeux, J.-P., & Christopoulos, A. (2016) · Cell · doi:10.1016/j.cell.2016.08.015 · Cited by 336
CXCR7/CXCR4 Heterodimer Constitutively Recruits β-Arrestin to Enhance Cell Migration
Décaillot, F. M., Kazmi, M. A., Lin, Y., Ray-Saha, S., Sakmar, T. P., & Sachdev, P. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.277038 · Cited by 333
Kohout, T. A., Nicholas, S. L., Perry, S. J., Reinhart, G., Junger, S., & Struthers, R. S. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402125200 · Cited by 333
Self-citationRen, X.-R., Reiter, E., Ahn, S., Kim, J., Chen, W., & Lefkowitz, R. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409534102 · Cited by 331
Lohse, M. J., Nuber, S., & Hoffmann, C. (2012) · Pharmacological Reviews · doi:10.1124/pr.110.004309 · Cited by 307
Lifting the lid on GPCRs: the role of extracellular loops
Wheatley, M., Wootten, D., Conner, M., Simms, J., Kendrick, R., Logan, R., Poyner, D., & Barwell, J. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01629.x · Cited by 304
CD28 induces immunostimulatory signals in dendritic cells via CD80 and CD86
Orabona, C., Grohmann, U., Belladonna, M. L., Fallarino, F., Vacca, C., Bianchi, R., Bozza, S., Volpi, C., Salomon, B. L., Fioretti, M. C., et al. (2004) · Nature Immunology · doi:10.1038/ni1124 · Cited by 302
New Roles for β-Arrestins in Cell Signaling: Not Just for Seven-Transmembrane Receptors
Lefkowitz, R. J., Rajagopal, K., & Whalen, E. J. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.11.007 · Cited by 301
Biased Receptor Signaling in Drug Discovery
Kenakin, T. (2019) · Pharmacological Reviews · doi:10.1124/pr.118.016790 · Cited by 294
Galandrin, S., & Bouvier, M. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.026716 · Cited by 291
Self-citationβ-arrestins: traffic cops of cell signaling
Lefkowitz, R. J., & Whalen, E. J. (2004) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2004.01.001 · Cited by 282
Nackley, A. G., Tan, K. S., Fecho, K., Flood, P., Diatchenko, L., & Maixner, W. (2007) · Pain · doi:10.1016/j.pain.2006.09.022 · Cited by 281
Functional Selectivity through Protean and Biased Agonism: Who Steers the Ship?
Kenakin, T. (2007) · Molecular Pharmacology · doi:10.1124/mol.107.040352 · Cited by 270
Avet, C., Mancini, A., Breton, B., Le Gouill, C., Hauser, A. S., Normand, C., Kobayashi, H., Gross, F., Hogue, M., Lukasheva, V., et al. (2022) · eLife · doi:10.7554/elife.74101 · Cited by 267
Self-citationEnergy Landscapes as a Tool to Integrate GPCR Structure, Dynamics, and Function
Deupi, X., & Kobilka, B. K. (2010) · Physiology · doi:10.1152/physiol.00002.2010 · Cited by 264
Allostery at G Protein-Coupled Receptor Homo- and Heteromers: Uncharted Pharmacological Landscapes
Smith, N. J., & Milligan, G. (2010) · Pharmacological Reviews · doi:10.1124/pr.110.002667 · Cited by 262
Swaminath, G., Deupi, X., Lee, T. W., Zhu, W., Thian, F. S., Kobilka, T. S., & Kobilka, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m502352200 · Cited by 257
Schröder, R., Janssen, N., Schmidt, J., Kebig, A., Merten, N., Hennen, S., Müller, A., Blättermann, S., Mohr-Andrä, M., Zahn, S., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1671 · Cited by 256
β-Arrestin-biased Agonism at the β2-Adrenergic Receptor
Drake, M. T., Violin, J. D., Whalen, E. J., Wisler, J. W., Shenoy, S. K., & Lefkowitz, R. J. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m708118200 · Cited by 254
Community guidelines for GPCR ligand bias: IUPHAR review 32
Kolb, P., Kenakin, T., Alexander, S. P. H., Bermudez, M., Bohn, L. M., Breinholt, C. S., Bouvier, M., Hill, S. J., Kostenis, E., Martemyanov, K. A., et al. (2022) · British Journal of Pharmacology · doi:10.1111/bph.15811 · Cited by 232
Tan, K. S., Nackley, A. G., Satterfield, K., Maixner, W., Diatchenko, L., & Flood, P. M. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2006.06.007 · Cited by 204
The oxytocin receptor antagonist atosiban inhibits cell growth via a “biased agonist” mechanism
Reversi, A., Rimoldi, V., Marrocco, T., Cassoni, P., Bussolati, G., Parenti, M., & Chini, B. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409945200 · Cited by 139
Agonist selectivity in the oxytocin/vasopressin receptor family: new insights and challenges
Chini, B., & Manning, M. (2007) · Biochemical Society Transactions · doi:10.1042/bst0350737 · Cited by 123
Zhang, X., Hartung, J. E., Bortsov, A. V., Kim, S., O'Buckley, S. C., Kozlowski, J., & Nackley, A. G. (2018) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2018.06.017 · Cited by 63
Targeting G protein coupled receptor-related pathways as emerging molecular therapies
Ghanemi, A. (2015) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2013.07.007 · Cited by 53
Metadata
- Authors
- Azzi, M., Charest, P. G., Angers, S., Rousseau, G., Kohout, T., Bouvier, M., & Piñeyro, G.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2003-09-17
- Volume
- 100
- Issue
- 20
- Pages
- 11406-11411
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2157562973
- Cited by
- 523
- References
- 36
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.